This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ZIOPHARM Announces Presentation Of Promising Nonclinical And Phase I Study Results Of Ad-RTS-IL-12 In Advanced Melanoma At ASGCT 16th Annual Meeting

BOSTON, May 16, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced promising results from nonclinical and Phase 1 studies in advanced melanoma using Ad-RTS-IL-12, a novel DNA-based therapeutic candidate. Findings were presented in an oral session at the 16 th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), held May 15-18 in Salt Lake City, Utah. A presentation of the study, titled "Nonclinical and Phase I Clinical Studies with a Regulated Adenoviral Gene Delivery of IL-12 Show Promising Clinical Activity in Unresectable Stage III/IV Melanoma," was delivered by John Nemunaitis, M.D., Executive Medical Director of Mary Crowley Medical Research Center.

For the studies, Ad-RTS-IL-12, utilizing RheoSwitch Therapeutic System® (RTS®) technology, was injected intratumorally. Gene expression and protein production were controlled through the administration of an oral activator ligand (INXN-1001). Nonclinical studies demonstrated a dose-dependent, immune mediated reduction in tumor volume in several different syngeneic tumor models, which led to a Phase 1 dose-escalation study in subjects with unresectable stage III/IV melanoma.

Study subjects (n=14) were treated in four dose cohorts of the activator ligand. Compelling clinical activity was observed in five of seven (71 percent) patients dosed at the two highest dose levels. These five patients experienced prominent inflammatory responses in injected and non-injected lesions and transient increases then decreases in the size of injected and non-injected lesions. Clinical activity in these higher dose cohorts coincided with the highest serum levels of IL-12 and IFN-γ, including a four-fold median increase from baseline at peak levels compared with lower dose cohorts. Flow cytometric analyses of peripheral blood mononuclear cell (PBMC) samples also revealed seven-fold and four-fold median increases from baseline at peak levels in absolute CD3+ and CD8+ T cell values, respectively, compared with lower dose cohorts. The most common related adverse events (AEs) included fever, nausea, vomiting, fatigue and arthralgia. One death occurred in the study, unrelated to treatment, due to septicemia secondary to cellulitis and colitis.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,050.75 +138.46 0.82%
S&P 500 1,995.83 +15.91 0.80%
NASDAQ 4,810.7880 +19.6360 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs